Novartis AG Operating Margin 2010-2024 | NVS

Current and historical operating margin for Novartis AG (NVS) over the last 10 years. The current operating profit margin for Novartis AG as of March 31, 2024 is 30.06%.
Novartis AG Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2024-03-31 $47.73B $10.52B 22.05%
2023-12-31 $46.66B $9.77B 20.94%
2023-09-30 $43.85B $8.34B 19.02%
2023-06-30 $42.55B $8.40B 19.75%
2023-03-31 $41.69B $7.71B 18.50%
2022-12-31 $43.46B $7.95B 18.28%
2022-09-30 $50.20B $9.47B 18.86%
2022-06-30 $52.79B $10.88B 20.60%
2022-03-31 $53.00B $12.13B 22.88%
2021-12-31 $52.88B $11.69B 22.11%
2021-09-30 $56.14B $15.52B 27.65%
2021-06-30 $51.56B $10.95B 21.24%
2021-03-31 $49.88B $9.82B 19.69%
2020-12-31 $49.90B $10.15B 20.35%
2020-09-30 $45.83B $5.58B 12.17%
2020-06-30 $49.53B $9.28B 18.73%
2020-03-31 $49.93B $9.59B 19.20%
2019-12-31 $48.68B $9.09B 18.67%
2019-09-30 $47.86B $8.63B 18.02%
2019-06-30 $46.76B $8.51B 18.19%
2019-03-31 $46.39B $8.27B 17.84%
2018-12-31 $46.10B $8.40B 18.23%
2018-09-30 $47.37B $9.11B 19.24%
2018-06-30 $48.67B $9.23B 18.96%
2018-03-31 $49.51B $9.08B 18.33%
2017-12-31 $50.14B $8.63B 17.21%
2017-09-30 $49.58B $8.01B 16.16%
2017-06-30 $49.23B $7.93B 16.10%
2017-03-31 $49.41B $7.74B 15.66%
2016-12-31 $49.44B $8.27B 16.72%
2016-09-30 $49.63B $8.49B 17.11%
2016-06-30 $49.78B $8.46B 16.99%
2016-03-31 $50.00B $8.64B 17.29%
2015-12-31 $50.39B $8.98B 17.82%
2015-09-30 $50.94B $9.65B 18.95%
2015-06-30 $51.75B $10.16B 19.62%
2015-03-31 $52.81B $11.06B 20.94%
2014-12-31 $53.63B $11.09B 20.68%
2014-09-30 $52.60B $11.23B 21.36%
2014-06-30 $52.21B $11.05B 21.17%
2014-03-31 $51.54B $10.90B 21.15%
2013-12-31 $52.72B $10.98B 20.83%
2013-09-30 $49.87B $11.20B 22.46%
2013-06-30 $51.00B $11.59B 22.73%
2013-03-31 $52.26B $11.67B 22.32%
2012-12-31 $51.97B $11.51B 22.14%
2012-09-30 $57.49B $9.89B 17.21%
2012-06-30 $58.48B $9.89B 16.92%
2012-03-31 $59.07B $10.11B 17.11%
2011-12-31 $59.38B $10.78B 18.16%
2011-09-30 $58.84B $12.15B 20.64%
2011-06-30 $56.63B $11.78B 20.81%
2011-03-31 $53.43B $11.42B 21.38%
2010-12-31 $51.56B $11.53B 22.35%
2010-09-30 $50.24B $11.70B 23.28%
2010-06-30 $48.71B $11.74B 24.11%
2010-03-31 $47.53B $11.15B 23.45%
2009-12-31 $45.10B $9.98B 22.13%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $220.139B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.732B 120.64
Novo Nordisk (NVO) Denmark $598.098B 45.96
Johnson & Johnson (JNJ) United States $366.658B 14.54
Merck (MRK) United States $315.030B 57.32
AbbVie (ABBV) United States $305.760B 15.80
AstraZeneca (AZN) United Kingdom $245.469B 21.34
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $127.725B 12.04
Innoviva (INVA) United States $1.113B 7.82